MA57022B1 - Composés et compositions d'induction de la chondrogenèse - Google Patents

Composés et compositions d'induction de la chondrogenèse

Info

Publication number
MA57022B1
MA57022B1 MA57022A MA57022A MA57022B1 MA 57022 B1 MA57022 B1 MA 57022B1 MA 57022 A MA57022 A MA 57022A MA 57022 A MA57022 A MA 57022A MA 57022 B1 MA57022 B1 MA 57022B1
Authority
MA
Morocco
Prior art keywords
compounds
compositions
induce
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA57022A
Other languages
English (en)
Inventor
James Paul Lajiness
Bao Nguyen
Hank Michael James Petrassi
Ha-Soon Choi
Jiqing Jiang
Zhicheng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA57022B1 publication Critical patent/MA57022B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci ; (i) ou un sel, tautomère ou stéréoisomère pharmaceutiquement acceptable de celui-ci, les variables étant telles que définies ici. La présente invention concerne en outre des compositions pharmaceutiques comprenant de tels composés ; et des procédés d'utilisation de tels composés pour traiter des lésions ou des lésions articulaires chez un mammifère, pour induire la production de cartilage hyalin ou pour induire la différenciation de cellules progénitrices chondrogéniques en chondrocytes matures.
MA57022A 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse MA57022B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse

Publications (1)

Publication Number Publication Date
MA57022B1 true MA57022B1 (fr) 2024-02-29

Family

ID=62837959

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050547A MA50547A (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse
MA57022A MA57022B1 (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050547A MA50547A (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse

Country Status (37)

Country Link
US (3) US11091499B2 (fr)
EP (3) EP3634967A1 (fr)
JP (2) JP7229945B2 (fr)
KR (1) KR102656524B1 (fr)
CN (1) CN110719913B (fr)
AR (1) AR113227A1 (fr)
AU (1) AU2018279306C1 (fr)
BR (1) BR112019025866A2 (fr)
CA (1) CA3063985A1 (fr)
CL (1) CL2019003564A1 (fr)
CO (1) CO2019013706A2 (fr)
CR (1) CR20190551A (fr)
CU (1) CU24577B1 (fr)
DK (1) DK3915994T3 (fr)
DO (1) DOP2019000305A (fr)
EA (1) EA201992858A1 (fr)
EC (1) ECSP19086712A (fr)
ES (1) ES2971319T3 (fr)
FI (1) FI3915994T3 (fr)
HR (1) HRP20240155T1 (fr)
HU (1) HUE065194T2 (fr)
IL (2) IL300755A (fr)
JO (1) JOP20190282A1 (fr)
LT (1) LT3915994T (fr)
MA (2) MA50547A (fr)
MX (1) MX2019014757A (fr)
PE (1) PE20200403A1 (fr)
PH (1) PH12019502764A1 (fr)
PL (1) PL3915994T3 (fr)
PT (1) PT3915994T (fr)
RS (1) RS65161B1 (fr)
SA (1) SA519410729B1 (fr)
SI (1) SI3915994T1 (fr)
TW (1) TWI782036B (fr)
UY (1) UY37759A (fr)
WO (1) WO2018225009A1 (fr)
ZA (1) ZA201907358B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
EP3891154B1 (fr) * 2018-12-06 2023-08-16 Novartis AG Dérivés de 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide pour l'induction de la chondrogenèse pour le traitement des lésions articulaires
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (fr) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2008008884A2 (fr) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition d'agrégation de peptide de bêta-amyloïde
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2757480A1 (fr) 2009-04-02 2010-10-07 Allergan, Inc. Antagonistes du recepteur de la prostaglandine e
KR20160015403A (ko) 2009-07-14 2016-02-12 더 스크립스 리서치 인스티튜트 중간엽 줄기 세포 분화
CA2818903C (fr) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridine-4-yl)pyrimidine-2-amine et son utilisation comme inhibiteur de caseine kinase 1 delta
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (fr) 2011-06-21 2012-12-27 Adispell, Inc. Modification de cognition
WO2013007765A1 (fr) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Composés tricycliques fusionnés utilisés en tant qu'inhibiteurs des janus kinases
KR102283996B1 (ko) * 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
AU2015259403B2 (en) * 2014-05-13 2017-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
US11753416B2 (en) 2023-09-12
LT3915994T (lt) 2024-02-26
KR102656524B1 (ko) 2024-04-12
IL300755A (en) 2023-04-01
CU24577B1 (es) 2022-02-04
PH12019502764A1 (en) 2020-07-13
CA3063985A1 (fr) 2018-12-13
MA50547A (fr) 2020-09-16
HUE065194T2 (hu) 2024-05-28
EP3634967A1 (fr) 2020-04-15
RU2019144107A (ru) 2021-07-09
JP7432778B2 (ja) 2024-02-16
WO2018225009A1 (fr) 2018-12-13
TWI782036B (zh) 2022-11-01
DOP2019000305A (es) 2019-01-15
JP7229945B2 (ja) 2023-02-28
IL271154B2 (en) 2023-07-01
IL271154B1 (en) 2023-03-01
JOP20190282A1 (ar) 2019-12-05
JP2020522550A (ja) 2020-07-30
JP2023062064A (ja) 2023-05-02
CU20190098A7 (es) 2020-10-20
PT3915994T (pt) 2024-02-15
HRP20240155T1 (hr) 2024-04-12
AU2018279306B2 (en) 2020-07-09
ES2971319T3 (es) 2024-06-04
PL3915994T3 (pl) 2024-05-20
US20210079010A1 (en) 2021-03-18
KR20200013046A (ko) 2020-02-05
CN110719913B (zh) 2022-10-28
RU2019144107A3 (fr) 2021-07-30
US20230365580A1 (en) 2023-11-16
US20210347784A1 (en) 2021-11-11
SA519410729B1 (ar) 2022-07-03
CL2019003564A1 (es) 2020-06-19
EP3915994A1 (fr) 2021-12-01
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
FI3915994T3 (fi) 2024-02-14
CO2019013706A2 (es) 2020-04-01
CR20190551A (es) 2020-01-28
ZA201907358B (en) 2022-04-28
RS65161B1 (sr) 2024-02-29
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (fr) 2023-11-22
EP3915994B9 (fr) 2024-02-28
BR112019025866A2 (pt) 2020-07-14
IL271154A (en) 2020-01-30
TW201902900A (zh) 2019-01-16
SI3915994T1 (sl) 2024-03-29
ECSP19086712A (es) 2019-12-27
AU2018279306A1 (en) 2019-12-05
NZ759434A (en) 2024-01-26
UY37759A (es) 2019-01-31
DK3915994T3 (da) 2024-02-19
US11091499B2 (en) 2021-08-17
EP4299123A2 (fr) 2024-01-03
AR113227A1 (es) 2020-02-19
PE20200403A1 (es) 2020-02-26
CN110719913A (zh) 2020-01-21
EP4299123A3 (fr) 2024-04-03

Similar Documents

Publication Publication Date Title
MA57022B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA54327B1 (fr) Inhibiteurs de kras g12c
MA30652B1 (fr) Composes organiques
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA30883B1 (fr) Nouveaux derives de 1,1 - dioxyde de 1.4 - benzothiepine substitues par des radicaux benzyle, leur procede de preparation, les produits pharmaceutiques comprenant ces composes et leur utilisation
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37405A1 (fr) Composés hétérocyclyle
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
EP0303506A3 (fr) Dérivés d'indole
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA32615B1 (fr) Inhibiteurs de cmet
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA33420B1 (fr) Dérivés fluorés de l'aminotriazole
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
TW200626146A (en) 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo